Nyxoah (NYXH)

• Market cap: $299M
• 1 day: 0.00%
• 5 days: -5.33%
• 1 month: -2.44%
• 3 months: -4.99%
• 6 months: 0.63%
• Year to date: 69.13%
• 1 year: 69.13%
• 5 years: -73.43%
• 10 years: -73.43%

About: Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Employees: 147

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

33% more capital invested

Capital invested by funds: $29.4M [Q2] → $39.1M (+$9.75M) [Q3]

0.37% less ownership

Funds ownership: 12.32% [Q2] → 11.95% (-0.37%) [Q3]

5% less funds holding

Funds holding: 21 [Q2] → 20 (-1) [Q3]

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $16 100% upside
• Avg. target: $16.50 106% upside
• High target: $17 113% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Edward White 24% 1-year accuracy 33 / 140 met price target	113% upside $17	Buy Reiterated	13 Dec 2024
Cantor Fitzgerald Ross Osborn 48% 1-year accuracy 23 / 48 met price target	100% upside $16	Overweight Reiterated	5 Nov 2024